Abstract:
Dolutegravir (DTG) is a pivotal antiretroviral medicine that has become the backbone of several HIV programmes, especially in sub-Saharan
African countries. It has recently replaced efavirenz as the preferred third drug for people initiating antiretroviral therapy in South Africa
(SA). Its tolerability, cost-effectiveness and favourable resistance profile have had a global influence on HIV management, including the recent
revision of the World Health Organization antiretroviral guidelines. As with any medicine, however, informed decisions are important. Despite
the several advantages DTG offers, additional data informing risks over benefits have emerged that warrant clinical attention before DTG is
prescribed. This article aims to give the primary care provider an overview of the benefits and risks associated with the roll-out of DTG in SA.
